Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Equity Average (2020 - 2026)

Journey Medical filings provide 6 years of Equity Average readings, the most recent being $28.9 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 86.32% to $28.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.9 million, a 86.32% increase, with the full-year FY2025 number at $26.0 million, up 28.46% from a year prior.
  • Equity Average hit $28.9 million in Q4 2025 for Journey Medical, up from $22.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $41.7 million in Q1 2022 to a low of -$6.3 million in Q3 2021.
  • Median Equity Average over the past 5 years was $16.1 million (2024), compared with a mean of $17.4 million.
  • Biggest five-year swings in Equity Average: surged 664.24% in 2022 and later crashed 90.17% in 2023.
  • Journey Medical's Equity Average stood at $15.2 million in 2021, then surged by 42.3% to $21.6 million in 2022, then dropped by 12.61% to $18.9 million in 2023, then dropped by 17.84% to $15.5 million in 2024, then surged by 86.32% to $28.9 million in 2025.
  • The last three reported values for Equity Average were $28.9 million (Q4 2025), $22.6 million (Q3 2025), and $20.4 million (Q2 2025) per Business Quant data.